Harm van Tinteren

32.9k total citations · 5 hit papers
340 papers, 17.1k citations indexed

About

Harm van Tinteren is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Harm van Tinteren has authored 340 papers receiving a total of 17.1k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Pulmonary and Respiratory Medicine, 140 papers in Oncology and 78 papers in Molecular Biology. Recurrent topics in Harm van Tinteren's work include Renal and related cancers (53 papers), Lung Cancer Treatments and Mutations (39 papers) and Renal cell carcinoma treatment (37 papers). Harm van Tinteren is often cited by papers focused on Renal and related cancers (53 papers), Lung Cancer Treatments and Mutations (39 papers) and Renal cell carcinoma treatment (37 papers). Harm van Tinteren collaborates with scholars based in Netherlands, United States and United Kingdom. Harm van Tinteren's co-authors include Victor J. Verwaal, Henk Boot, F.A.N. Zoetmulder, Serge van Ruth, Simon Horenblas, Gooike W. van Slooten, Eelco de Bree, Egbert F. Smit, Otto S. Hoekstra and Sjoerd C. Bruin and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Harm van Tinteren

336 papers receiving 16.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

2003 1.5k citations Harm van Tinteren et al. Journal of Clinical Oncology profile →
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

2018 919 citations Harm van Tinteren et al. profile →
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer

2008 764 citations Harm van Tinteren et al. profile →
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial

2002 576 citations Harm van Tinteren, Otto S. Hoekstra et al. profile →
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

2014 384 citations Harm van Tinteren et al. profile →

Peers

Countries citing papers authored by Harm van Tinteren

Since Specialization

Citations

This map shows the geographic impact of Harm van Tinteren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harm van Tinteren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harm van Tinteren more than expected).

Fields of papers citing papers by Harm van Tinteren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harm van Tinteren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harm van Tinteren. The network helps show where Harm van Tinteren may publish in the future.

Co-authorship network of co-authors of Harm van Tinteren

This figure shows the co-authorship network connecting the top 25 collaborators of Harm van Tinteren. A scholar is included among the top collaborators of Harm van Tinteren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harm van Tinteren. Harm van Tinteren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias 2024 ·Blood ·Elisabeth Salzer, Janine Stutterheim, Branko Cuglievan, Blake Tomkinson, Mollie Leoni, Harm van Tinteren, Alwin D. R. Huitema, Marieke Willemse, Gwen Nichols, Francisco Bautista, Sarah K. Tasian, Todd M. Cooper, C. Michel Zwaan	1
2	Omission of adjuvant chemotherapy in patients with completely necrotic Wilms tumor stage I and radiotherapy in stage III: The 30‐year SIOP‐RTSG experience 2024 ·Pediatric Blood & Cancer ·Gordan Vujanić, Norbert Graf, Ellen D’Hooghe, Kathy Pritchard‐Jones, Christophe Bergeron, Harm van Tinteren, Rhoikos Furtwängler, (unknown)	1
3	MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma 2023 ·Frontiers in Oncology ·Thomas F. Eleveld, (unknown), Linda Schild, (unknown), Lindy K. Alles, Marli E. Ebus, (unknown), Harm van Tinteren, Huib N. Caron, Jan Köster, Max M. van Noesel, Godelieve A.M. Tytgat, Selma Eising, Rogier Versteeg, M. Emmy M. Dolman, Jan J. Molenaar	6
4	Radiologic versus Segmentation Measurements to Quantify Wilms Tumor Volume on MRI in Pediatric Patients 2023 ·Cancers ·(unknown), Alida F. W. van der Steeg, Marc H. W. A. Wijnen, (unknown), Harm van Tinteren, Marry M. van den Heuvel‐Eibrink, Annemieke S. Littooij, Bas H. M. van der Velden	8
5	Impact of the COVID‐19 pandemic on paediatric renal tumour presentation and management, a SIOP renal tumour study group study 2023 ·Cancer Medicine ·(unknown), (unknown), (unknown), Catriona Duncan, (unknown), Arnauld Verschuur, Beatriz de Camargo, Henrike E. Karim‐Kos, (unknown), Filippo Spreafico, Gema Ramírez, Norbert Graf, Harm van Tinteren, Kathy Pritchard‐Jones, Marry M. van den Heuvel‐Eibrink	4
6	Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia 2022 ·Leukemia ·(unknown), Erica Brivio, Harm van Tinteren, Susan R. Rheingold, Allison Barz Leahy, Britta Vormoor, Maureen M. O’Brien, Jeremy D. Rubinstein, Krzysztof Kałwak, Barbara De Moerloose, Elad Jacoby, Peter Bader, Monica López‐Duarte, Bianca F. Goemans, Franco Locatelli, Peter M. Hoogerbrugge, Friso Calkoen, C. Michel Zwaan	13
7	Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature 2021 ·Cancers ·(unknown), Filippo Spreafico, Ronald R. de Krijger, Jarno Drost, Jesper Brok, Daniela Perotti, Harm van Tinteren, Rajkumar Venkatramani, Jan Godziński, Christian Rübe, James I. Geller, Norbert Graf, Marry M. van den Heuvel‐Eibrink, Annelies M. C. Mavinkurve‐Groothuis	34
8	First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis 2019 ·SHILAP Revista de lepidopterología ·(unknown), Harm van Tinteren, (unknown), (unknown), (unknown)	4
9	Evaluation of needle biopsy as a potential risk factor for local recurrence of Wilms tumour in the SIOP WT 2001 trial 2019 ·European Journal of Cancer ·Sabine Irtan, Harm van Tinteren, Norbert Graf, Marry M. van den Heuvel‐Eibrink, Hugo A. Heij, Christophe Bergeron, Beatriz de Camargo, Tomás Acha, Filippo Spreafico, Gordan Vujanić, Mark Powis, Bruce Okoye, (unknown), Jan Godziński, Kathy Pritchard‐Jones	21
10	Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy 2016 ·Clinical Cancer Research ·Siu W. Lam, Nienke M. Nota, Agnes Jager, Monique M.E.M. Bos, (unknown), Ankie M.T. van der Velden, Johanneke E.A. Portielje, Aafke H. Honkoop, Harm van Tinteren, Epie Boven	17
11	ecancermedicalscience 2016 ·ecancermedicalscience ·Ingrid Kappers, Marieke A. Vollebergh, Harm van Tinteren, (unknown), (unknown), Johannes M.G. Bonfrèr, Houke M. Klomp, Nico van Zandwijk, Michel M. van den Heuvel	7
12	TREATMENT OF RELAPSED WILMS TUMOUR (WT) PATIENTS: EXPERIENCE WITH TOPOTECAN 2014 ·Data Archiving and Networked Services (DANS) ·(unknown), (unknown), (unknown), Harm van Tinteren, Gordan Vujanić, Kathy Pritchard‐Jones, Lisa Howell, Norbert Graf, (unknown), (unknown), Filippo Spreafico	3
13	Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·Eva E. Schaake, Ingrid Kappers, Henk Codrington, Renato A. Valdés Olmos, Hendrik J. Teertstra, Renée van Pel, Jacobus A. Burgers, Harm van Tinteren, Houke M. Klomp	68
14	Characteristics and outcome of stage II and III non-anaplastic Wilms’ tumour treated according to the SIOP trial and study 93-01 2012 ·European Journal of Cancer ·Norbert Graf, Harm van Tinteren, Christophe Bergeron, F Pein, Marry M. van den Heuvel‐Eibrink, Bengt Sandstedt, Jens‐Peter Schenk, Jan Godziński, Foppe Oldenburger, Rhoikos Furtwängler, Jan de Kraker	61
15	Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer 2011 ·Clinical Cancer Research ·Vincent A. de Weger, Annelies W. Turksma, Quirinus J.M. Voorham, Zelda Euler, Herman Bril, Alfons J. van den Eertwegh, Elisabeth Bloemena, Herbert M. Pinedo, Jan B. Vermorken, Harm van Tinteren, Gerrit A. Meijer, Erik Hooijberg	54
16	Doxorubicin can be safely omitted from the treatment of stage II/III, intermediate risk histology wilms tumour: results of the siop wt 2001 randomised trial [Abstract] 2011 ·ORCA Online Research @Cardiff (Cardiff University) ·Kathy Pritchard‐Jones, Norbert Graf, Christophe Bergeron, Beatriz de Camargo, (unknown), Bengt Sandstedt, Ivo Leuschner, Gordan Vujanić, Liliane Boccon‐Gibod, Jan Godziński, Foppe Oldenburger, Harm van Tinteren, Jan de Kraker	1
17	Is the absolute blastema volume after preoperative chemotherapy in nephroblastoma relevant for prognosis? [Abstract] 2011 ·ORCA Online Research @Cardiff (Cardiff University) ·Norbert Graf, Harm van Tinteren, Kathy Pritchard‐Jones, Christophe Bergeron, Bengt Sandstedt, Ivo Leuschner, Gordan Vujanić, Liliane Boccon‐Gibod, Marry van den Heuvel‐Eibrink, Beatriz de Camargo, Filippo Spreafico, Foppe Oldenburger, Jan Godziński, Jan de Kraker	4
18	SIGNIFICANCE OF LYMPH NODE INVOLVEMENT IN NEPHROBLASTOMA 2010 ·UCL Discovery (University College London) ·Paul Grundy, Harm van Tinteren, Anderson, (unknown), Norbert Graf, Kathy Pritchard‐Jones	4
19	A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy 2007 ·Contemporary Clinical Trials ·Remco de Bree, Lisa van der Putten, Otto S. Hoekstra, Dirk J. Kuik, Carin A. Uyl‐de Groot, Harm van Tinteren, C. René Leemans, Maarten Boers	12
20	Traditional Versus Up-Front [ ¹⁸ F] Fluorodeoxyglucose–Positron Emission Tomography Staging of Non–Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study 2006 ·Journal of Clinical Oncology ·Gerarda J.M. Herder, Henk Kramer, Otto S. Hoekstra, Egbert F. Smit, Jan Pruim, Harm van Tinteren, Emile F.I. Comans, Paul Verboom, Carin A. Uyl‐de Groot, (unknown), Marinus A. Paul, Maarten Boers, Pieter E. Postmus, G. J. J. Teule, Harry J.M. Groen	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact